Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy


YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., ...More

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.59-63, 2022 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 6 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.14744/ejmo.2022.78280
  • Journal Name: EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.59-63
  • Keywords: Hyperprogressive disease, immun checkpoint inhibitors, immunotherapy, PILE score
  • Hacettepe University Affiliated: Yes

Abstract

Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter overall survival (OS) compared with those having a progressive disease (PD). Therefore, biomarkers are needed to differentiate HPD and PD.